Adeno-associated viral delivery of a microRNA targeting ATXN1 provides therapeutic benefit in mouse models of spinocerebellar ataxia type 1. Keiser et al. assess the translatability of this approach using adult rhesus macaques, and show that targeted delivery to deep cerebellar nuclei silences endogenous ATXN1 mRNA in multiple SCA1-affected sites.